What quality standards does the manufacturer meet?

The company has GMP approval by the SFDA of China and produces over 100 kinds of medicines across 7 series.

What are the available payment terms?

Terms of payment include LC and T/T.

What is the average lead time during peak season?

The peak season lead time is one month.

Sodium Chloride Intravenous Infusion Manufacturer

Name: Sodium Chloride Intravenous Infusion Manufacturer
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 853804485

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.17-0.20

20,000 Pieces

Sample price:US$0.10/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Injection

Model NO.

100ml~2L

Suitable for

Elderly, Adult

State

Liquid

Shape

Injection

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

20023252

Transport Package

Plastic Bottle

Specification

50ml~1000ml

Trademark

SHIMEN

Origin

Hebei

HS Code

3004909099

Production Capacity

1000000

Key features

Clinical Indications: Treats dehydration, coma, and low-chloride metabolic alkali poisoning.

Manufacturer Scale: Established in 1948 with over 3000 employees and USD 58 million capital.

Production Capacity: Annual output exceeds 1200 million bottles including soft plastic packaging.

Quality Certification: Manufactured with GMP approval by the SFDA of China.

Global Market Reach: Products sold to South America, Africa, Asia, and Oceania.

Product Form: Colorless clear liquid with salt flavor, suitable for injection.

Versatile Applications: Used for eye and wound washing, and labor induction with water bag.

Chemical Composition: 0.9% Sodium Chloride (NaCl), molecular weight 58.44.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤9.50hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.

Product Q&A

Q:What are the main clinical indications for this product?

It is indicated for dehydration caused by various conditions, coma due to hypertonicity non-ketosis diabetes, and low-chloride metabolic alkali poisoning.

Q:What is the physical appearance of the solution?

The product is a colorless clear liquid with a salt flavor.

Q:How is the product used for external applications?

External use includes washing eyes and wounds, and it can be used for the induction of labor with a water bag.

Q:What is the manufacturing background of the company?

Shijiazhuang No.4 Pharmaceutical Co., Ltd. was established in 1948, is a large foreign-invested enterprise with over 3000 employees and USD 58 million capital.

Q:What is the annual production capacity for large volume I.V solutions?

The yearly output has reached more than 1200 million bottles, including 40 million bottles in soft plastic packaging (500ml, 250ml, 100ml).